"Compounds For Use In The Treatment Of Epilepsy" in Patent Application Approval Process (USPTO 20230323366).
In: Gene Therapy Weekly, 2023-10-30, S. 3630-3630
serialPeriodical
Zugriff:
Keywords: Antisense Oligonucleotides; Antisense Technology; Bioengineering; Biotechnology; Brain Diseases and Conditions; Cell Membrane; Cellular Structures; Central Nervous System Diseases and Conditions; Drugs and Therapies; Epilepsy; Gene Therapy; Genetics; Health and Medicine; Intercellular Junctions; Nervous System Diseases and Conditions; Neurologic Manifestations; Patent Application; Seizures; Synapses; Therapeutics; Therapy EN Antisense Oligonucleotides Antisense Technology Bioengineering Biotechnology Brain Diseases and Conditions Cell Membrane Cellular Structures Central Nervous System Diseases and Conditions Drugs and Therapies Epilepsy Gene Therapy Genetics Health and Medicine Intercellular Junctions Nervous System Diseases and Conditions Neurologic Manifestations Patent Application Seizures Synapses Therapeutics Therapy 3630 3630 1 10/30/23 20231030 NES 231030 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A patent application by the inventors BOILEAU, Celine (Marseille, FR); CREPEL, Valerie (Marseille, FR); DANOS, Olivier (Rockville, MD, US); DEFORGES, Severine (Bruges, FR); MASANTE, Julie (Saint Jean D'illac, FR); MERCER, Andrew (Rockville, MD, US); NULLE, Christophe (Pessac, FR); PERET, Angelique (Marseille, FR), filed on July 9, 2021, was made available online on October 12, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. In another embodiment, the polynucleotide has at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or more) sequence identity to a nucleic acid sequence of SEQ ID NOs: 14, 15, 18, or 19, particularly wherein the antisense oligonucleotide does not have the nucleic acid sequence of SEQ ID NOs: 1, 2, or 3. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Compounds For Use In The Treatment Of Epilepsy" in Patent Application Approval Process (USPTO 20230323366).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2023-10-30, S. 3630-3630 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|